Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer - Episode 6

Exploring TROP2 Expression in Patients with NSCLC

,

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer
    EP. 2: ADCs in Development for the Treatment of Lung Cancer
    EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
    EP. 4: HER2-Directed Agents in NSCLC
    EP. 5: Targeting HER3 in EGFR-Mutant NSCLC
    Now Viewing
    EP. 6: Exploring TROP2 Expression in Patients with NSCLC
    x